Viking Therapeutics VKTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's cash & equivalents?
- Viking Therapeutics (VKTX) reported cash & equivalents of $118.12M in Q1 2026.
- How has Viking Therapeutics's cash & equivalents changed year-over-year?
- Viking Therapeutics's cash & equivalents increased by 211.3% year-over-year, from $37.94M to $118.12M.
- What is the long-term trend for Viking Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Viking Therapeutics's cash & equivalents has grown at a 41.6% compound annual growth rate (CAGR), from $29.12M to $165.81M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.